Intermediate junctional epidermolysis bullosa caused by mutations in the COL17A1 gene is characterized by the frequent development of blisters and erosions on the skin and mucous membranes. The rarity of the disease and the heterogeneity of the underlying mutations renders therapy developments challenging. However, the high number of short in-frame exons facilitates the use of antisense oligonucleotides (AON) to restore collagen 17 (C17) expression by inducing exon skipping. In a personalized approach, we designed and tested three AONs in combination with a cationic liposomal carrier for their ability to induce skipping of COL17A1 exon 7 in 2D culture and in 3D skin equivalents. We show that AON-induced exon skipping excludes the targeted exon from pre-mRNA processing, which restores the reading frame, leading to the expression of a slightly truncated protein. Furthermore, the expression and correct deposition of C17 at the dermal–epidermal junction indicates its functionality. Thus, we assume AON-mediated exon skipping to be a promising tool for the treatment of junctional epidermolysis bullosa, particularly applicable in a personalized manner for rare genotypes.
Recessive dystrophic epidermolysis bullosa (RDEB) is a blistering disorder caused by mutations in COL7A1 that encodes for the anchoring fibrils of type VII collagen. Our lab has demonstrated that non-viral gene delivery by polymer is able to restore the expression of type VII collagen (C7) to human RDEB skin and could overcome the possibility of generating an immune response when compared to viral vectors. Silencing caused by viral promoters is a major problem for an episomal non-viral gene therapy. To increase the safety profile of COL7A1 therapy more focus needs to be in the DNA cassette itself as an important tool for resisting transgene silencing and extending C7 expression. The feasibility of this approach was demonstrated using a novel gene delivery polymer as a non-viral vector combined with minicircle (MC) DNA encoding full-length COL7A1 under the control of three different promoters, including human COL7A1 promoter (C7p) as a tissue-specific promoter, human elongation factor one alpha (EF1a) and cytomegalovirus (CMV). The three MC plasmid (MC-C7p-C7, MC-EF1a-C7 and MC-CMV-C7) were used to transfect human RDEB Keratinocytes (K) and Fibroblasts (F). Type VII collagen expression was detected and compared among the three promoters and confirmed in in vitro at the gene level using RT-qPCR as well as at the protein level using immuno-blotting. All the three MC constructs are capable of achieving expression levels comparable to native protein from healthy human primary cells, there is an indication of a 20 fold C7 expression change detected in transfected RDEBF cells compared to un-transfected cells. A multifaceted analysis of the promoters expression is being performed. In conclusion, our results suggest that an optimal promoter selection is an important enhancement that can be added to the minicircle vector in our non-viral system and therefore will enhance transgene expression and help to reduce immuneimmunogenicity.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.